Payment overview · 2025
General Payments
$144.39
8 reported records · 5 companies
Healthcare provider profile · identity verified
Mark S. Fraley, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · COLORADO SPRINGS, CO · NPI 1134163819
Verified facts
What the public records show
CMS Open Payments records show Mark S. Fraley, D.O. received $144.39 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 53.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.66 | 53.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.36 | 12.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.37 | 12.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.24 | 11.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.76 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $144.39 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 251 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 214 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
251 | 77 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
214 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 999 | 306 |
| Levothyroxine Sodium | Levothyroxine Sodium | 601 | 172 |
| Lisinopril | Lisinopril | 511 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 342 | 104 |
| Losartan Potassium | Losartan Potassium | 284 | 86 |
| Jardiance | Empagliflozin | 251 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 224 | 62 |
| Ozempic | Semaglutide | 214 | 43 |
| Metformin Hcl | Metformin Hcl | 211 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 61 |
| Metformin Hcl Er | Metformin Hcl | 198 | 64 |
| Gabapentin | Gabapentin | 194 | 56 |
| Simvastatin | Simvastatin | 194 | 55 |
| Omeprazole | Omeprazole | 171 | 60 |
| Alendronate Sodium | Alendronate Sodium | 165 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 48 |
| Alprazolam | Alprazolam | 154 | 27 |
| Tramadol Hcl | Tramadol Hcl | 152 | 31 |
| Trazodone Hcl | Trazodone Hcl | 144 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 141 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 134 | 43 |
| Sertraline Hcl | Sertraline Hcl | 123 | 32 |
| Allopurinol | Allopurinol | 120 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 35 |
| Famotidine | Famotidine | 111 | 31 |
| Potassium Chloride | Potassium Chloride | 95 | 30 |
| Ezetimibe | Ezetimibe | 88 | 27 |
| Fenofibrate | Fenofibrate | 83 | 24 |
| Montelukast Sodium | Montelukast Sodium | 82 | 27 |
| Celecoxib | Celecoxib | 79 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 27 |
| Eliquis | Apixaban | 66 | 20 |
| Valsartan | Valsartan | 66 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 20 |
| Buspirone Hcl | Buspirone Hcl | 61 | 19 |
| Meloxicam | Meloxicam | 61 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 13 |
| Glipizide Er | Glipizide | 52 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 27 |
| Finasteride | Finasteride | 46 | 15 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 15 |
| Irbesartan | Irbesartan | 41 | 12 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 13 |
| Estradiol | Estradiol | 40 | 19 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Carvedilol | Carvedilol | 36 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Furosemide | Furosemide | 34 | 14 |
| Ibuprofen | Ibuprofen | 34 | 11 |
| Ramipril | Ramipril | 34 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Belsomra | Suvorexant | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $144.39 · 8 records | Novo Nordisk Inc | Auvelity, CAPVAXIVE, JARDIANCE, M-M-R II, Ozempic, Rybelsus, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error